

# Aaron Rosenberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7522917/publications.pdf>

Version: 2024-02-01

52  
papers

893  
citations

623734

14  
h-index

477307

29  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 231-234.	1.3	0
2	Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. <i>Leukemia Research</i> , 2022, 119, 106885.	0.8	2
3	Second primary malignancies in multiple myeloma: A review. <i>Blood Reviews</i> , 2021, 46, 100757.	5.7	30
4	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 5.	6.2	11
5	Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E114-E117.	4.1	5
6	Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. <i>Frontiers in Oncology</i> , 2021, 11, 649209.	2.8	36
7	Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 345-354.e4.	0.4	4
8	Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 4726-4736.	7.0	1
9	Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e611-e618.	0.4	0
10	Trust and shared decision-making among individuals with multiple myeloma: A qualitative study. <i>Cancer Medicine</i> , 2021, 10, 8040-8057.	2.8	18
11	An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia. <i>Blood</i> , 2021, 138, 2352-2352.	1.4	0
12	A Comprehensive Cancer Center Experience with Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 4394-4394.	1.4	2
13	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 1317-1330.	10.7	155
14	High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2605-2613.	1.3	4
15	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , 2020, 44, 100672.	5.7	135
16	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 453-458.	0.4	2
17	Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Journal of Hematology (Brossard, Quebec)</i> , 2020, 9, 79-83.	1.0	1
18	Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center. <i>Blood</i> , 2020, 136, 28-28.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Second Primary Malignancy Risk Among HIV-Uninfected and HIV-Infected Survivors of Hodgkin Lymphoma: A 30-Year Follow-up Population-Based Study. <i>Blood</i> , 2020, 136, 15-17.	1.4	1
20	Treatment Patterns and Survival in Older Adults with Diffuse Large B-cell Lymphoma: A Population-Based Study. <i>Journal of Registry Management</i> , 2020, 47, 135-145.	0.1	2
21	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 78-85.	6.3	20
22	Survival after diffuse large B-cell lymphoma among children, adolescents, and young adults in California, 2001-2014: A population-based study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27559.	1.5	6
23	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. <i>Cancer</i> , 2018, 124, 1938-1945.	4.1	40
24	Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 210-218.	0.4	24
25	Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 536-542.	2.1	4
26	Impact of latency time on survival for adolescents and young adults with a second primary malignancy. <i>Cancer</i> , 2018, 124, 1260-1268.	4.1	14
27	Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. <i>JAMA Oncology</i> , 2017, 3, 1554.	7.1	99
28	Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. <i>British Journal of Haematology</i> , 2017, 178, 72-80.	2.5	38
29	Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. <i>British Journal of Haematology</i> , 2017, 178, 319-326.	2.5	87
30	Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. <i>Blood Cancer Journal</i> , 2017, 7, e605-e605.	6.2	22
31	Incidence of Venous Thromboembolism and Impact on Mortality in Patients with Primary CNS Lymphoma: A Population Based Study. <i>Blood</i> , 2017, 130, 754-754.	1.4	3
32	Breast cancer and thrombosis: timing matters. <i>Blood</i> , 2016, 127, 793-794.	1.4	7
33	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 684-692.e3.	0.4	15
34	Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. <i>Clinical Biochemistry</i> , 2016, 49, 1202-1204.	1.9	19
35	Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. <i>American Journal of Hematology</i> , 2016, 91, 560-565.	4.1	32
36	Assessing the Effect of Injectable or Oral Routes of Treatment Administration on Patient-Reported Outcomes and out-of-Pocket Costs Among Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5931-5931.	1.4	3

#	ARTICLE	IF	CITATIONS
37	Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 846-846.	1.4	3
38	Efficacy and Tolerability of Hyper-CVAD in Adult Acute Lymphoblastic Patients: A Retrospective Analysis at a Comprehensive Cancer Center. <i>Blood</i> , 2016, 128, 5195-5195.	1.4	0
39	Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study. <i>Blood</i> , 2016, 128, 3982-3982.	1.4	2
40	Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California. <i>Blood</i> , 2016, 128, 391-391.	1.4	0
41	Extracorporeal Photophoresis in Reduced Intensity Conditioning: 14 Year Follow-up of 206 Patients Reveals an Efficacious Regimen with Low Rates of GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S35-S36.	2.0	0
42	The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment. <i>Blood</i> , 2015, 126, 1991-1991.	1.4	0
43	Incidence and Evaluation of Incidental Abnormal Bone Marrow Signal on Magnetic Resonance Imaging. <i>Scientific World Journal</i> , The, 2014, 2014, 1-6.	2.1	9
44	Multiple Myeloma and Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorders (PTLD): Examination of Outcomes and Prognostication in the Modern Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S148-S150.	0.4	0
45	Improvement of Blood Glucose Control on the Bone Marrow Transplant (BMT) Unit: A Retrospective Review of Our Quality Improvement Pilot Program. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S202.	2.0	0
46	Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis. <i>Blood</i> , 2014, 124, 3170-3170.	1.4	4
47	Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder (HL-PTLD) after Solid Organ Transplant (SOT): A Comprehensive and Comparative Analysis of Disease Characteristics, Prognosis, and Survival. <i>Blood</i> , 2014, 124, 502-502.	1.4	1
48	Photopheresis As Part of Conditioning Reduces Incidence of Severe Graft Versus Host Disease: Fourteen Year Follow-up of a Novel Reduced Intensity Regimen for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5924-5924.	1.4	0
49	A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab Era. <i>Blood</i> , 2014, 124, 2609-2609.	1.4	0
50	Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. <i>Blood</i> , 2014, 124, 2595-2595.	1.4	0
51	Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 787-794.	4.1	32
52	Multiple Myeloma and Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorders (PTLD): Examination Of Outcomes and Prognostication In The Modern Era. <i>Blood</i> , 2013, 122, 1899-1899.	1.4	0